+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Papillomavirus Vaccine Market by Vaccine Type, End User, Distribution Channel, Age Group, Gender - Global Forecast to 2030- Product Image
Human Papillomavirus Vaccine Market by Vaccine Type, End User, Distribution Channel, Age Group, Gender - Global Forecast to 2030- Product Image
Sale

Human Papillomavirus Vaccine Market by Vaccine Type, End User, Distribution Channel, Age Group, Gender - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4858029
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Human Papillomavirus (HPV) vaccine market is evolving rapidly, driven by policy shifts, scientific innovation, and changing public health needs across diverse regions. As healthcare ecosystems adapt, senior decision-makers require sharp, data-driven insights to navigate complexity and strengthen long-term strategy.

Market Snapshot: Human Papillomavirus Vaccine Market Growth

The global Human Papillomavirus vaccine market is experiencing steady growth, expanding from USD 4.60 billion in 2024 to USD 4.93 billion in 2025. Projections indicate continued expansion at a CAGR of 7.06%, with the market anticipated to reach USD 6.93 billion by 2030. Expansion is fueled by rising awareness, enhanced vaccine formulations, and the adoption of digital health solutions. This creates a dynamic commercial environment where access, innovation, and public health priorities converge to shape the future landscape.

Scope & Segmentation

This report analyzes the HPV vaccine market across multiple strategic dimensions to enable effective market entry, investment, and operational planning:

  • Vaccine Types: Focus on 9-valent, bivalent, and quadrivalent formulations, each offering varying degrees of protection and adoption based on geographic and economic context.
  • End User: Analysis of clinics, hospitals, and public health centers as distribution and administration hubs, each with differing outreach strategies and roles in immunization programs.
  • Distribution Channels: Includes hospital pharmacies, online platforms, and retail pharmacies, representing both traditional and emerging access points, particularly for adults and catch-up dosing.
  • Age Groups: Segmentation of demand across age bands 9-14, 15-26, and 27 years and above, reflecting both routine and targeted catch-up strategies for expanded coverage.
  • Gender: Assessment of vaccination dynamics among female and male populations, supporting efforts for gender-neutral immunization initiatives.
  • Regions Covered: Comprehensive coverage of Americas, Europe, Middle East & Africa, and Asia-Pacific, highlighting unique regulatory, funding, and demographic factors.
  • Key Players Assessed: Leading global and regional manufacturers, including Merck & Co., GlaxoSmithKline, Shanghai Zerun Biotech, Xiamen Innovax Biotech, Shenzhen Kangtai, Walvax, Beijing Zhifei Lvzhu, and Panacea Biotec Ltd.

Technology & Digital Integration

  • Next-Generation Platforms: Includes research and deployment of mRNA and precision adjuvant systems, expanding potential for more robust and flexible vaccine offerings.
  • Data Analytics: Integration of digital health tools for appointment scheduling, outcome tracking, and adherence monitoring supports program optimization and better risk management.

Key Takeaways for Decision-Makers

  • Widespread adoption of the nine-valent vaccine positions it as the standard for advanced protection, while cost-sensitive settings maintain interest in other formulations.
  • Government initiatives and targeted educational campaigns have successfully expanded vaccine uptake among younger cohorts, reducing disease burden in priority populations.
  • Digital health platforms streamline access and monitoring, improving both operational efficiency and completion rates for immunization programs.
  • Regional disparities in regulatory approvals, distribution infrastructure, and funding mechanisms require nuanced strategies for market penetration and sustained growth.
  • Gender-neutral vaccination strategies are closing historical gaps in uptake, enhancing population-wide immunity and opening new market segments.
  • Strategic partnerships and licensing agreements between key industry players accelerate new product launches and facilitate regional adaptation.

Tariff Impact on Human Papillomavirus Vaccine Market

Recent adjustments to U.S. tariff schedules have affected the Human Papillomavirus vaccine supply chain by increasing import costs for bulk vaccine components. Manufacturers have responded by evaluating localized production options, renegotiating terms with suppliers, and adapting pricing models in select districts. These developments have prompted public health programs to secure longer-term procurement contracts, helping stabilize vaccine access despite short-term cost fluctuations. Tariff policy, therefore, remains a critical factor in shaping availability and affordability in both domestic and international markets.

Methodology & Data Sources

This analysis employs a rigorous approach combining expert interviews with immunologists, public health leaders, and supply chain managers, alongside review of regulatory filings, clinical studies, and industry publications. All data was triangulated across multiple reliable sources to validate accuracy and underlying trends. Segmentation is mapped using epidemiological and infrastructure data for a robust, multi-layered market view.

Why This Report Matters

  • Delivers actionable insights to inform investment, procurement, and partnership decisions within the global HPV vaccine space.
  • Provides a detailed segmentation analysis, supporting tailored go-to-market and operational optimization strategies for diverse regions and demographics.
  • Highlights the impact of policy, technology, and regulatory shifts, equipping decision-makers to anticipate and respond to market changes confidently.

Conclusion

The Human Papillomavirus vaccine market is poised for continued evolution shaped by science, policy, and market innovation. Decision-makers equipped with granular, validated insights will be best positioned to drive strategic growth and public health advancement in this critical sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Papillomavirus Vaccine Market, by Vaccine Type
8.1. Introduction
8.2. 9-Valent
8.3. Bivalent
8.4. Quadrivalent
9. Human Papillomavirus Vaccine Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Hospitals
9.4. Public Health Centers
10. Human Papillomavirus Vaccine Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Human Papillomavirus Vaccine Market, by Age Group
11.1. Introduction
11.2. 15-26 Years
11.3. 27 Years And Above
11.4. 9-14 Years
12. Human Papillomavirus Vaccine Market, by Gender
12.1. Introduction
12.2. Female
12.3. Male
13. Americas Human Papillomavirus Vaccine Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Human Papillomavirus Vaccine Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Human Papillomavirus Vaccine Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Shanghai Zerun Biotech Co., Ltd.
16.3.4. Xiamen Innovax Biotech Co., Ltd.
16.3.5. Shenzhen Kangtai Biological Products Co., Ltd.
16.3.6. Walvax Biotechnology Co., Ltd.
16.3.7. Beijing Zhifei Lvzhu Biopharma Co., Ltd.
16.3.8. Panacea Biotec Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET MULTI-CURRENCY
FIGURE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 42. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 46. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 68. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 69. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 72. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 73. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 74. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 78. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 83. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 84. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 88. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 89. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 98. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 99. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 103. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 104. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 108. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 114. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 118. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 123. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 124. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 138. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 143. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 144. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 148. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 149. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 153. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 154. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 158. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 159. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 163. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 164. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 167. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 174. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 175. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 179. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 180. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 184. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 185. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 194. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 204. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 205. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 208. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 224. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 234. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2024
TABLE 235. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Human Papillomavirus Vaccine market report include:
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Shanghai Zerun Biotech Co., Ltd.
  • Xiamen Innovax Biotech Co., Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Zhifei Lvzhu Biopharma Co., Ltd.
  • Panacea Biotec Ltd.

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.93 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.93 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report by Type (Bivalent, Quadrivalent, Nonavalent), Disease (Cervical Cancer, Anal Cancer), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report by Type (Bivalent, Quadrivalent, Nonavalent), Disease (Cervical Cancer, Anal Cancer), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 195 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report - Product Image

Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Market Report 2025 - Product Image

Human Papillomavirus (HPV) Vaccine Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the HPV Vaccine Market

The HPV Vaccine is a type of cancer vaccine used to prevent infection from the human papillomavirus (HPV). HPV is a virus that can cause cervical cancer, as well as other types of cancer. The HPV Vaccine is typically administered to adolescents and young adults, and is recommended by the World Health Organization (WHO) as part of routine immunization programs. The vaccine is available in both a bivalent and quadrivalent form, and is designed to protect against the two most common types of HPV that cause cervical cancer. The HPV Vaccine market is a rapidly growing segment of the cancer vaccine market. It is estimated that the global HPV Vaccine market will reach $4.5 billion by 2027, driven by increasing awareness of the virus and its associated health risks, as well as the availability of the vaccine in many countries. Some of the major companies in the HPV Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and CSL. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.